---
title: "投資者是否應該購買禮來的股票？"
description: "投資者對公司的減肥治療方案感到興奮，但可能忽視了令人振奮的新療法管線"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260741285.md"
published_at: "2025-10-11T12:07:27.000Z"
---

# 投資者是否應該購買禮來的股票？

> 投資者對公司的減肥治療方案感到興奮，但可能忽視了令人振奮的新療法管線

Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies.

### Related Stocks

- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-HK/news/276070062.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| Eli Lilly just delivered fantastic news to investors | Eli Lilly shares have climbed in the double digits this year. | [Link](https://longbridge.com/zh-HK/news/269703566.md) |
| Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance | Anixa Biosciences CEO Dr. Amit Kumar announced that 2026 will be a pivotal year for the company as it advances a breast  | [Link](https://longbridge.com/zh-HK/news/275508535.md) |
| Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | [Link](https://longbridge.com/zh-HK/news/275926557.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。